UNSPSC 51432404: Zofenoprilat

This classification denotes an ace inhibitor with the molecular formula C15H19NO3S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4G4WDK2YBS, chemically known as (2S,4S)-1-[(2S)-2-methyl-3-sulfanylpropanoyl]-4-phenylsulfanylpyrrolidine-2-carboxylic acid but generally known as zofenoprilat, which bears US NIH Compound Identifier 3034048. European Medicines Agency schedules zofenoprilat in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00171MIG.

Most nations schedule zofenoprilat under HS 29339990 and SITC 51577. As of Q4 2014, ZOFENOPRILAT remains the US FDA Preferred Term for this commodity. Zofenoprilat bears US NLM identifiers UMLS ID C0085065 and NCI Concept Code C95293. SMILES: CC(CS)C(=O)N1CC(CC1C(=O)O)SC2=CC=CC=C2.

UNSPSC 51432404 Zofenoprilat, a Commodity code, encompasses prescription medications supplied directly to state and local health agencies, fire rescue services, and pharmacy benefit programs. State and local governments procure under this code when stocking emergency medical supplies, supporting pharmacy benefit initiatives, and maintaining formulary compliance across public health systems. Issuing bodies include municipal fire departments (Tampa Fire Rescue), state health and human services commissions (Texas HHS), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance / MMCAP). The work ranges from tactical procurement of specific advanced life support medications for emergency medical services to strategic market research on direct-to-manufacturer pharmacy initiatives and cooperative contracting for generic pharmaceuticals across multiple state and local jurisdictions.

Activity appears concentrated in the South and Upper Midwest. The City of Tampa issued an IFB (Bid No. 26P00188) closing April 8, 2026, for Advanced Life Support Medications totaling four drug line items (Labetalol HCI, Epinephrine, Adenosine, Diltiazem) with an estimated contract value of $40,000 and a Small Local Business Enterprise sheltered market designation offering a 5 percent bid discount. Texas HHS issued an RFI (No. HHS0017013) on April 3, 2026, seeking vendor capabilities for direct-to-manufacturer prescription fulfillment models outside traditional pharmacy benefit manager and group purchasing organization channels. MMCAP, administering a multistate cooperative covering Minnesota and Oregon, issued an RFP (S1070000015802) due March 26, 2026, to establish multiple-award contracts for generic pharmaceuticals and OTC products distributed through three authorized wholesalers, with a two-year term and evaluation weighted 75 percent on price competitiveness and 25 percent on compliance, EDI capability, and administrative fee structure.